SCHEMBL23099050

SCHEMBL23099050

Cc1cnn2ccc(Oc3ccccc3)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 5/20 0.45
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
HPGD P15428 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LTA4H P09960 3/20 0.38
TSHR P16473 1/20 0.38
EPHB3 P54753 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
AKR1C3 P42330 1/20 0.37
BAZ2B Q9UIF8 2/20 0.36
BAZ2A Q9UIF9 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23087176 0.81 PRMT5 (0.46) MAP2K1PRMT5WDR77ALDH1A1KDM4E
SCHEMBL23938061 0.80 EPHB3 (0.46) ALDH1A1KDM4EEPHB3L3MBTL1TDP1
SCHEMBL23099061 0.76 PRMT5 (0.45) PRMT5WDR77HPGDALDH1A1KDM4E
SCHEMBL23099178 0.76 PRMT5 (0.44) PRMT5WDR77HPGDALDH1A1KDM4E
SCHEMBL23087685 0.70 SCN5A (0.44) HPGDALDH1A1KDM4ELTA4HTSHR
SCHEMBL24370193 0.69 EPHB3 (0.43) EPHB3MAPTLMNASMN1; SMN2MEN1
SCHEMBL24149172 0.69 PIK3CA (0.44)
SCHEMBL24349062 0.69 PIK3CD (0.39) EPHB3LMNANPC1RAB9A
SCHEMBL30896342 0.67 HAO1 (0.45) PRMT5LTA4HL3MBTL1TDP1
SCHEMBL24338893 0.66 MAP4K4 (0.34) HSD17B10EPHB3LMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479551-B2 MTA-cooperative PRMT5 inhibitors Mirati Therapeutics, Inc. (US) 2022-10-25 US disclosed
US-20210078994-A1 MTA-Cooperative PRMT5 Inhibitors Mirati Therapeutics, Inc. 2021-03-18 US disclosed
US-20210079003-A1 MTA-Cooperative PRMT5 Inhibitors Mirati Therapeutics, Inc. 2021-03-18 US disclosed
WO-2021050915-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479551-B2 MTA-cooperative PRMT5 inhibitors PRMT5, PRMT1, PRMT3 MAP2K1 2079/4885PRMT5 1/4885WDR77 133/4885
US-20210079003-A1 MTA-Cooperative PRMT5 Inhibitors PRMT5, PRMT1, PRMT3 MAP2K1 2113/4885PRMT5 1/4885WDR77 226/4885
US-20210078994-A1 MTA-Cooperative PRMT5 Inhibitors PRMT5, PRMT1, PRMT3 MAP2K1 2113/4885PRMT5 1/4885WDR77 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.